■ 영문 제목 : Global Non-Hodgkin Lymphoma Therapeutics Market 2023-2027
|
 | ■ 상품코드 : IRTNTR70886-23
■ 조사/발행회사 : Technavio
■ 발행일 : 2023년 2월 ■ 페이지수 : 약120
■ 작성언어 : 영문
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (24시간 이내)
■ 조사대상 지역 : 북미, 유럽, 아시아, 기타 지역
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
Single User (1명 열람용) | USD2,500 ⇒환산₩3,375,000 | 견적의뢰/주문/질문 |
Enterprise License (동일기업내 공유가능) | USD4,000 ⇒환산₩5,400,000 | 견적의뢰/주문/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
Technavio사의 본 조사 보고서는 세계의 비호지킨 림프종 치료제 시장 규모가 2023년부터 2027년 사이에 5,427.51백만 달러에 이르며, 예측 기간 중 연평균 성장률은 8.14%가 될 것으로 전망하고 있습니다. 본 보고서는 세계의 비호지킨 림프종 치료제 시장에 대해 광범위한 조사를 실시하여, 개요, 시장 현황, 시장 규모 예측, 과거 시장 규모, Five Force 분석, 유통 채널별 (병원 약국, 소매 약국, 온라인 약국, 기타) 분석, 치료별 (면역 요법, 표적요법, 화학 요법) 분석, 고객 현황, 지역별 (북미, 유럽, 아시아, 미국, 영국, 독일, 중국, 캐나다, 기타 지역) 분석, 기업 분석 등의 내용를 수록하고 있습니다. 덧붙여 본 조사 자료는 AstraZeneca Plc, Baxter International Inc., Bayer AG, BeiGene Ltd., Biogen Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc. 와 같은 기업 정보를 포함하고 있습니다.
・개요
・시장 현황
・시장 규모 예측
・과거 시장 규모
・Five Force 분석
・세계의 비호지킨 림프종 치료제 시장 규모 : 유통 채널별
- 병원 약국 채널의 시장 규모
- 소매 약국 채널의 시장 규모
- 온라인 약국 채널의 시장 규모
- 기타 유통 채널의 시장 규모
・세계의 비호지킨 림프종 치료제 시장 규모 : 치료별
- 비호지킨 림프종 면역 요법의 시장 규모
- 비호지킨 림프종 표적 요법의 시장 규모
- 비호지킨 림프종 화학 요법의 시장 규모
・고객 현황
・세계의 비호지킨 림프종 치료제 시장 규모 : 지역별
- 북미의 비호지킨 림프종 치료제 시장 규모
- 유럽의 비호지킨 림프종 치료제 시장 규모
- 아시아 비호지킨 림프종 치료제 시장 규모
- 미국의 비호지킨 림프종 치료제 시장 규모
- 영국의 비호지킨 림프종 치료제 시장 규모
- 독일의 비호지킨 림프종 치료제 시장 규모
- 중국의 비호지킨 림프종 치료제 시장 규모
- 캐나다의 비호지킨 림프종 치료제 시장 규모
- 기타 지역의 비호지킨 림프종 치료제 시장 규모
・성장 요인/과제/동향
・기업 현황
・기업 분석
Technavio 사는 이익, 가격, 경쟁, 프로모션과 같은 주요 매개 변수를 분석하여, 다수의 소스로부터 데이터를 조사, 통합 및 합산하여 비호지킨 림프종 치료제 시장에 대한 상세하고 종합적인 결과를 제공합니다. 또한, 주요 산업의 영향 요인을 분석하여 시장의 다양한 관점을 제시합니다. 제시된 데이터는 포괄적이고 신뢰할 수 있으며, 1차 및 2차에 걸친 광범위한 조사 결과입니다. 덧붙여 Technavio 사의 시장 조사 보고서는 정확한 비호지킨 림프종 치료제 시장 성장을 예측하기 위해, 정성적 및 정량적 조사를 사용하여, 명확한 경쟁 현황과 상세한 벤더 선택 방법 및 분석을 제공합니다. |
■ 보고서 개요Global Non-Hodgkin Lymphoma Therapeutics Market 2023-2027Technavio has been monitoring the non-Hodgkin lymphoma therapeutics market and is forecast to grow by $5427.51 mn during 2022-2027, accelerating at a CAGR of 8.14% during the forecast period. Our report on the non-Hodgkin lymphoma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by recent approvals and strong pipeline, growing geriatric population, and special drug designations.
Technavio’s non-Hodgkin lymphoma therapeutics market is segmented as below:
By Distribution Channel
• Hospital pharmacy
• Retail pharmacy
• Online pharmacy
• Others
By Therapy
• Immunotherapy
• Targeted therapy
• Chemotherapy
By Geographical Landscape
• North America
• Europe
• Asia
• Rest of World (ROW)
This study identifies the research grants and funding as one of the prime reasons driving the non-Hodgkin lymphoma therapeutics market growth during the next few years. Also, growing awareness about cancer and increase in patient assistance programs and reimbursements will lead to sizable demand in the market.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the non-Hodgkin lymphoma therapeutics market covers the following areas:
• Non-Hodgkin lymphoma therapeutics market sizing
• Non-Hodgkin lymphoma therapeutics market forecast
• Non-Hodgkin lymphoma therapeutics market industry analysis
Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading non-Hodgkin lymphoma therapeutics market vendors that include AstraZeneca Plc, Baxter International Inc., Bayer AG, BeiGene Ltd., Biogen Inc., Bristol Myers Squibb Co., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson Services Inc., Merck KGaA, Novartis AG, Pfizer Inc., Seagen Inc., Spectrum Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd. Also, the non-Hodgkin lymphoma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
■ 보고서 목차• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Therapy
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global non-hodgkin lymphoma therapeutics market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global non-hodgkin lymphoma therapeutics market 2017 – 2021 ($ million)
o 4.2 Therapy Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
o 4.3 Distribution channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Distribution Channel
o 6.1 Market segments
o Exhibit 30: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 6.2 Comparison by Distribution Channel
o Exhibit 32: Chart on Comparison by Distribution Channel
o Exhibit 33: Data Table on Comparison by Distribution Channel
o 6.3 Hospital pharmacy – Market size and forecast 2022-2027
o Exhibit 34: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
o 6.4 Retail pharmacy – Market size and forecast 2022-2027
o Exhibit 38: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
o 6.5 Online pharmacy – Market size and forecast 2022-2027
o Exhibit 42: Chart on Online pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Data Table on Online pharmacy – Market size and forecast 2022-2027 ($ million)
o Exhibit 44: Chart on Online pharmacy – Year-over-year growth 2022-2027 (%)
o Exhibit 45: Data Table on Online pharmacy – Year-over-year growth 2022-2027 (%)
o 6.6 Others – Market size and forecast 2022-2027
o Exhibit 46: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 49: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 6.7 Market opportunity by Distribution Channel
o Exhibit 50: Market opportunity by Distribution Channel ($ million)
• 7 Market Segmentation by Therapy
o 7.1 Market segments
o Exhibit 51: Chart on Therapy – Market share 2022-2027 (%)
o Exhibit 52: Data Table on Therapy – Market share 2022-2027 (%)
o 7.2 Comparison by Therapy
o Exhibit 53: Chart on Comparison by Therapy
o Exhibit 54: Data Table on Comparison by Therapy
o 7.3 Immunotherapy – Market size and forecast 2022-2027
o Exhibit 55: Chart on Immunotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Immunotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Immunotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Immunotherapy – Year-over-year growth 2022-2027 (%)
o 7.4 Targeted therapy – Market size and forecast 2022-2027
o Exhibit 59: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)
o 7.5 Chemotherapy – Market size and forecast 2022-2027
o Exhibit 63: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 64: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
o Exhibit 65: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
o Exhibit 66: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Therapy
o Exhibit 67: Market opportunity by Therapy ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 69: Chart on Market share By Geographical Landscape 2022-2027 (%)
o Exhibit 70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 71: Chart on Geographic comparison
o Exhibit 72: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 73: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 77: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 81: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 85: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 89: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 UK – Market size and forecast 2022-2027
o Exhibit 93: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.9 Germany – Market size and forecast 2022-2027
o Exhibit 97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.10 China – Market size and forecast 2022-2027
o Exhibit 101: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 102: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 103: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.11 Canada – Market size and forecast 2022-2027
o Exhibit 105: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 106: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 107: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 108: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 109: Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 110: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 111: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 112: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 113: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 114: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 115: Matrix on vendor position and classification
o 12.3 AstraZeneca Plc
o Exhibit 116: AstraZeneca Plc – Overview
o Exhibit 117: AstraZeneca Plc – Product / Service
o Exhibit 118: AstraZeneca Plc – Key news
o Exhibit 119: AstraZeneca Plc – Key offerings
o 12.4 BeiGene Ltd.
o Exhibit 120: BeiGene Ltd. – Overview
o Exhibit 121: BeiGene Ltd. – Business segments
o Exhibit 122: BeiGene Ltd. – Key offerings
o Exhibit 123: BeiGene Ltd. – Segment focus
o 12.5 Biogen Inc.
o Exhibit 124: Biogen Inc. – Overview
o Exhibit 125: Biogen Inc. – Product / Service
o Exhibit 126: Biogen Inc. – Key offerings
o 12.6 Bristol Myers Squibb Co.
o Exhibit 127: Bristol Myers Squibb Co. – Overview
o Exhibit 128: Bristol Myers Squibb Co. – Product / Service
o Exhibit 129: Bristol Myers Squibb Co. – Key news
o Exhibit 130: Bristol Myers Squibb Co. – Key offerings
o 12.7 Eisai Co. Ltd.
o Exhibit 131: Eisai Co. Ltd. – Overview
o Exhibit 132: Eisai Co. Ltd. – Business segments
o Exhibit 133: Eisai Co. Ltd. – Key offerings
o Exhibit 134: Eisai Co. Ltd. – Segment focus
o 12.8 F. Hoffmann La Roche Ltd.
o Exhibit 135: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 136: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 137: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 138: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 139: F. Hoffmann La Roche Ltd. – Segment focus
o 12.9 Gilead Sciences Inc.
o Exhibit 140: Gilead Sciences Inc. – Overview
o Exhibit 141: Gilead Sciences Inc. – Product / Service
o Exhibit 142: Gilead Sciences Inc. – Key news
o Exhibit 143: Gilead Sciences Inc. – Key offerings
o 12.10 GlaxoSmithKline Plc
o Exhibit 144: GlaxoSmithKline Plc – Overview
o Exhibit 145: GlaxoSmithKline Plc – Business segments
o Exhibit 146: GlaxoSmithKline Plc – Key offerings
o Exhibit 147: GlaxoSmithKline Plc – Segment focus
o 12.11 Johnson and Johnson Services Inc.
o Exhibit 148: Johnson and Johnson Services Inc. – Overview
o Exhibit 149: Johnson and Johnson Services Inc. – Business segments
o Exhibit 150: Johnson and Johnson Services Inc. – Key news
o Exhibit 151: Johnson and Johnson Services Inc. – Key offerings
o Exhibit 152: Johnson and Johnson Services Inc. – Segment focus
o 12.12 Merck KGaA
o Exhibit 153: Merck KGaA – Overview
o Exhibit 154: Merck KGaA – Business segments
o Exhibit 155: Merck KGaA – Key news
o Exhibit 156: Merck KGaA – Key offerings
o Exhibit 157: Merck KGaA – Segment focus
o 12.13 Novartis AG
o Exhibit 158: Novartis AG – Overview
o Exhibit 159: Novartis AG – Business segments
o Exhibit 160: Novartis AG – Key offerings
o Exhibit 161: Novartis AG – Segment focus
o 12.14 Pfizer Inc.
o Exhibit 162: Pfizer Inc. – Overview
o Exhibit 163: Pfizer Inc. – Product / Service
o Exhibit 164: Pfizer Inc. – Key news
o Exhibit 165: Pfizer Inc. – Key offerings
o 12.15 Seagen Inc.
o Exhibit 166: Seagen Inc. – Overview
o Exhibit 167: Seagen Inc. – Product / Service
o Exhibit 168: Seagen Inc. – Key offerings
o 12.16 Spectrum Pharmaceuticals Inc.
o Exhibit 169: Spectrum Pharmaceuticals Inc. – Overview
o Exhibit 170: Spectrum Pharmaceuticals Inc. – Product / Service
o Exhibit 171: Spectrum Pharmaceuticals Inc. – Key offerings
o 12.17 Teva Pharmaceutical Industries Ltd.
o Exhibit 172: Teva Pharmaceutical Industries Ltd. – Overview
o Exhibit 173: Teva Pharmaceutical Industries Ltd. – Business segments
o Exhibit 174: Teva Pharmaceutical Industries Ltd. – Key news
o Exhibit 175: Teva Pharmaceutical Industries Ltd. – Key offerings
o Exhibit 176: Teva Pharmaceutical Industries Ltd. – Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 177: Inclusions checklist
o Exhibit 178: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 179: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 180: Research methodology
o Exhibit 181: Validation techniques employed for market sizing
o Exhibit 182: Information sources
o 13.5 List of abbreviations
o Exhibit 183: List of abbreviations
Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits6: Executive Summary – Chart on Market Segmentation by Therapy
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global non-hodgkin lymphoma therapeutics market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Therapy Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits31: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Distribution Channel
Exhibits33: Data Table on Comparison by Distribution Channel
Exhibits34: Chart on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Hospital pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Hospital pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Retail pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Retail pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits42: Chart on Online pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits43: Data Table on Online pharmacy – Market size and forecast 2022-2027 ($ million)
Exhibits44: Chart on Online pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits45: Data Table on Online pharmacy – Year-over-year growth 2022-2027 (%)
Exhibits46: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits47: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits48: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits49: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits50: Market opportunity by Distribution Channel ($ million)
Exhibits51: Chart on Therapy – Market share 2022-2027 (%)
Exhibits52: Data Table on Therapy – Market share 2022-2027 (%)
Exhibits53: Chart on Comparison by Therapy
Exhibits54: Data Table on Comparison by Therapy
Exhibits55: Chart on Immunotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Immunotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Immunotherapy – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Immunotherapy – Year-over-year growth 2022-2027 (%)
Exhibits59: Chart on Targeted therapy – Market size and forecast 2022-2027 ($ million)
Exhibits60: Data Table on Targeted therapy – Market size and forecast 2022-2027 ($ million)
Exhibits61: Chart on Targeted therapy – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on Targeted therapy – Year-over-year growth 2022-2027 (%)
Exhibits63: Chart on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits64: Data Table on Chemotherapy – Market size and forecast 2022-2027 ($ million)
Exhibits65: Chart on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits66: Data Table on Chemotherapy – Year-over-year growth 2022-2027 (%)
Exhibits67: Market opportunity by Therapy ($ million)
Exhibits68: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits69: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits70: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits71: Chart on Geographic comparison
Exhibits72: Data Table on Geographic comparison
Exhibits73: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits102: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits103: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits105: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits106: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits107: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits108: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits109: Market opportunity By Geographical Landscape ($ million)
Exhibits110: Impact of drivers and challenges in 2022 and 2027
Exhibits111: Overview on Criticality of inputs and Factors of differentiation
Exhibits112: Overview on factors of disruption
Exhibits113: Impact of key risks on business
Exhibits114: Vendors covered
Exhibits115: Matrix on vendor position and classification
Exhibits116: AstraZeneca Plc – Overview
Exhibits117: AstraZeneca Plc – Product / Service
Exhibits118: AstraZeneca Plc – Key news
Exhibits119: AstraZeneca Plc – Key offerings
Exhibits120: BeiGene Ltd. – Overview
Exhibits121: BeiGene Ltd. – Business segments
Exhibits122: BeiGene Ltd. – Key offerings
Exhibits123: BeiGene Ltd. – Segment focus
Exhibits124: Biogen Inc. – Overview
Exhibits125: Biogen Inc. – Product / Service
Exhibits126: Biogen Inc. – Key offerings
Exhibits127: Bristol Myers Squibb Co. – Overview
Exhibits128: Bristol Myers Squibb Co. – Product / Service
Exhibits129: Bristol Myers Squibb Co. – Key news
Exhibits130: Bristol Myers Squibb Co. – Key offerings
Exhibits131: Eisai Co. Ltd. – Overview
Exhibits132: Eisai Co. Ltd. – Business segments
Exhibits133: Eisai Co. Ltd. – Key offerings
Exhibits134: Eisai Co. Ltd. – Segment focus
Exhibits135: F. Hoffmann La Roche Ltd. – Overview
Exhibits136: F. Hoffmann La Roche Ltd. – Business segments
Exhibits137: F. Hoffmann La Roche Ltd. – Key news
Exhibits138: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits139: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits140: Gilead Sciences Inc. – Overview
Exhibits141: Gilead Sciences Inc. – Product / Service
Exhibits142: Gilead Sciences Inc. – Key news
Exhibits143: Gilead Sciences Inc. – Key offerings
Exhibits144: GlaxoSmithKline Plc – Overview
Exhibits145: GlaxoSmithKline Plc – Business segments
Exhibits146: GlaxoSmithKline Plc – Key offerings
Exhibits147: GlaxoSmithKline Plc – Segment focus
Exhibits148: Johnson and Johnson Services Inc. – Overview
Exhibits149: Johnson and Johnson Services Inc. – Business segments
Exhibits150: Johnson and Johnson Services Inc. – Key news
Exhibits151: Johnson and Johnson Services Inc. – Key offerings
Exhibits152: Johnson and Johnson Services Inc. – Segment focus
Exhibits153: Merck KGaA – Overview
Exhibits154: Merck KGaA – Business segments
Exhibits155: Merck KGaA – Key news
Exhibits156: Merck KGaA – Key offerings
Exhibits157: Merck KGaA – Segment focus
Exhibits158: Novartis AG – Overview
Exhibits159: Novartis AG – Business segments
Exhibits160: Novartis AG – Key offerings
Exhibits161: Novartis AG – Segment focus
Exhibits162: Pfizer Inc. – Overview
Exhibits163: Pfizer Inc. – Product / Service
Exhibits164: Pfizer Inc. – Key news
Exhibits165: Pfizer Inc. – Key offerings
Exhibits166: Seagen Inc. – Overview
Exhibits167: Seagen Inc. – Product / Service
Exhibits168: Seagen Inc. – Key offerings
Exhibits169: Spectrum Pharmaceuticals Inc. – Overview
Exhibits170: Spectrum Pharmaceuticals Inc. – Product / Service
Exhibits171: Spectrum Pharmaceuticals Inc. – Key offerings
Exhibits172: Teva Pharmaceutical Industries Ltd. – Overview
Exhibits173: Teva Pharmaceutical Industries Ltd. – Business segments
Exhibits174: Teva Pharmaceutical Industries Ltd. – Key news
Exhibits175: Teva Pharmaceutical Industries Ltd. – Key offerings
Exhibits176: Teva Pharmaceutical Industries Ltd. – Segment focus
Exhibits177: Inclusions checklist
Exhibits178: Exclusions checklist
Exhibits179: Currency conversion rates for US$
Exhibits180: Research methodology
Exhibits181: Validation techniques employed for market sizing
Exhibits182: Information sources
Exhibits183: List of abbreviations
|
※본 조사보고서 [세계의 비호지킨 림프종 치료제 시장 (2023년~2027년)] (코드 : IRTNTR70886-23) 판매에 관한 면책사항을 반드시 확인하세요. |
※본 조사보고서 [세계의 비호지킨 림프종 치료제 시장 (2023년~2027년)] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!